U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H12N5O5P
Molecular Weight 289.1851
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GS-438

SMILES

NC1=NC2=C(N=CN2CCOCP(O)(O)=O)C(=O)N1

InChI

InChIKey=NZVORGQIEFTOQZ-UHFFFAOYSA-N
InChI=1S/C8H12N5O5P/c9-8-11-6-5(7(14)12-8)10-3-13(6)1-2-18-4-19(15,16)17/h3H,1-2,4H2,(H2,15,16,17)(H3,9,11,12,14)

HIDE SMILES / InChI

Molecular Formula C8H12N5O5P
Molecular Weight 289.1851
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Rabacfosadine was approved in 2017 under the brand name Tanovea-CA1 for the treatment of canine lymphoma. In addition, this drug has demonstrated effectiveness against non-Hodgkin's lymphoma in dogs, as well as canine cutaneous T-cell lymphoma, and relapsed canine B-cell lymphoma. Rabacfosadine a prodrug, which is hydrolyzed intracellularly to the metabolites, 9-(2-phosphonylmethoxyethyl)-N6-cyclopropyl-2,6-diaminopurine (cPrPMEDAP) and 9-(2-phosphonylmethoxyethyl) guanine (PMEG). PMEG is then converted to its active phosphorylated form, which is a chain-terminating inhibitor of the replicative deoxyribonucleic acid (DNA) polymerases.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.7 µM [EC50]
PubMed

PubMed

TitleDatePubMed
Tanovea® for the treatment of lymphoma in dogs.
2018 Aug
Patents

Patents

Sample Use Guides

Administer TANOVEA-CA1 at 1 mg/kg body weight as a 30-minute intravenous infusion, once every three weeks, for up to five doses. Stepwise dose reductions to 0.8 mg/kg and 0.66 mg/kg or dose delays may be used to manage adverse reactions.
Route of Administration: Intravenous
Substance Class Chemical
Created
by admin
on Sat Dec 16 08:35:45 GMT 2023
Edited
by admin
on Sat Dec 16 08:35:45 GMT 2023
Record UNII
N9YOI96LPP
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GS-438
Common Name English
9-(2-(PHOSPHONOMETHOXY)ETHYL)GUANINE
Systematic Name English
PMEG
Common Name English
J291.906K
Code English
9-((2-PHOSPHONYLMETHOXY)ETHYL)GUANINE [MI]
Common Name English
(2-(2-AMINO-6-HYDROXY-9H-PURIN-9-YL)ETHOXY)METHYLPHOSPHONIC ACID
Systematic Name English
PHOSPHONIC ACID, P-((2-(2-AMINO-1,6-DIHYDRO-6-OXO-9H-PURIN-9-YL)ETHOXY)METHYL)-
Systematic Name English
Code System Code Type Description
CAS
114088-58-3
Created by admin on Sat Dec 16 08:35:45 GMT 2023 , Edited by admin on Sat Dec 16 08:35:45 GMT 2023
PRIMARY
WIKIPEDIA
PMEG (antiviral)
Created by admin on Sat Dec 16 08:35:45 GMT 2023 , Edited by admin on Sat Dec 16 08:35:45 GMT 2023
PRIMARY
FDA UNII
N9YOI96LPP
Created by admin on Sat Dec 16 08:35:45 GMT 2023 , Edited by admin on Sat Dec 16 08:35:45 GMT 2023
PRIMARY
PUBCHEM
135409438
Created by admin on Sat Dec 16 08:35:45 GMT 2023 , Edited by admin on Sat Dec 16 08:35:45 GMT 2023
PRIMARY
EPA CompTox
DTXSID90150649
Created by admin on Sat Dec 16 08:35:45 GMT 2023 , Edited by admin on Sat Dec 16 08:35:45 GMT 2023
PRIMARY
MERCK INDEX
m12245
Created by admin on Sat Dec 16 08:35:45 GMT 2023 , Edited by admin on Sat Dec 16 08:35:45 GMT 2023
PRIMARY
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
ACTIVE MOIETY